The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis (NCT06928246)
Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (16 items) and avoid the listed exclusions (12 items).
Location: University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: Phase 1b:
- Age less than 18 years old
- Pregnant or breastfeeding
- Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
- Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
- Has used topical therapy for treatment of AD within 4 weeks Phase 2:
- Patients enrolled in Phase 1
- Age less than 18 years old
- Pregnant or breastfeeding
- Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
- Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
- Has used topical therapy for treatment of AD within 4 weeks
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- UPMC Department of Dermatology — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (412) 647-2013
Email: ruhlcl@upmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis (AD)
- Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Fargo, North Dakota
- Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes — Edmonton, Alberta
- Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population — Aguascalientes, Aguascalientes
- A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Phoenix, Arizona
- Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Birmingham, Alabama
Explore by condition: All Atopic Dermatitis (AD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.